PALI Stock Forecast: Palisade Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Palisade Bio, Inc. is $7.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 19 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Palisade Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (46): The share price has been relatively steady.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PALI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PALI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $5.00 |
| 11 Nov 2026 | Piper Sandler | Maintains | Overweight | $25 → $16 |
| 13 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 9 Oct 2026 | Raymond James | Initiates | Outperform | $6.00 |
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 23 July 2026 | Oppenheimer | Initiates | Outperform | $8.00 |
| 9 Apr 2026 | Wolfe Research | Initiates | Outperform | $7.00 |
| 26 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Feb 2026 | Stifel | Initiates | Buy | — |
| 9 Jan 2026 | B. Riley Securities | Initiates | Buy | — |
| 30 Dec 2025 | Clear Street | Initiates | Buy | — |
| 29 Dec 2025 | Piper Sandler | Initiates | Overweight | — |
| 13 May 2025 | Brookline Capital | Maintains | Buy | — |
| 20 Nov 2024 | Brookline Capital | Initiates | Buy | — |
| 13 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 1 May 2024 | Maxim Group | Reiterates | Buy | — |
| 16 Apr 2024 | Maxim Group | Maintains | Buy | — |
| 17 Nov 2023 | Maxim Group | Upgrade | Buy | — |
| 16 May 2023 | Ladenburg Thalmann | Maintains | Buy | — |
| 30 Mar 2023 | Maxim Group | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PALI.
This page is one stock. Monday covers all of them.
PALI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PALI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Palisade Bio, Inc. returned −64.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PALI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.0×
- Price / sales
- 318.5×
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 93% of US stocks
Cheaper than 2% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −75.6%
- Return on assets
- −47.9%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Palisade Bio, Inc. has a market value of $166.9M and an enterprise value of $52.3M.
Revenue in the twelve months to 30 June 2026: $500K.
Net income over the same four quarters: −$31.9M, a −6388.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$18.2M.
Trailing P/E: 1.0×.
Palisade Bio, Inc. employs 14 people — $36K of revenue per employee.
Data provided by Twelve Data
PALI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PALI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Palisade Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PALI
What is the PALI stock price forecast for 2026-2027?
The median 12-month analyst price target for Palisade Bio, Inc. is $7.5, with estimates ranging from $5 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PALI stock a buy right now?
Of the 10 analysts covering Palisade Bio, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palisade Bio, Inc. 19 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PALI?
As at 21 Nov 2026, Palisade Bio, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (46 of 100).
Will PALI stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts is $7.5, and Ticker Nerd's factor model ranks Palisade Bio, Inc. 19 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PALI stock forecast for 2030?
No analyst covering Palisade Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PALI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $16 over the next 12 months.
How has PALI stock performed over the past year?
Palisade Bio, Inc. returned -64.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Palisade Bio, Inc. do?
Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
About Palisade Bio, Inc.
Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company’s current pipeline also includes additional gastrointestinal-focused programs aimed at protecting the intestinal barrier and addressing postoperative complications. Palisade Bio works with research and development partners to advance its drug candidates through clinical studies and product development, positioning the company within the specialty biopharmaceutical segment of the healthcare market.
CEO Mr. J. D. Finley · 14 employees · United States · https://www.palisadebio.com